Latest news with #CitiBiotechPrivateAccessDay
Yahoo
23-04-2025
- Business
- Yahoo
Tenpoint Therapeutics Ltd. to Participate at Citi Biotech Private Access Day
LONDON & SEATTLE, April 23, 2025--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd. ("Tenpoint"), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, will participate in one-on-one meetings at the virtual Citi Biotech Private Access Day on April 24. About Tenpoint TherapeuticsTenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. BRIMOCHOL PF has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) and has submitted its NDA to the US FDA. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, AlbionVC, British Business Bank (formerly British Patient Capital), Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and Wille AG. To learn more, visit and connect on LinkedIn. View source version on Contacts Media and Investors Andrew Korda or Donna LaVoieLaVoieHealthSciencetenpoint@ 617-865-0043 Ophthalmic Trade Media Relations Michele GrayGray Communications, LLCmichele@ 917-449-9250 Sign in to access your portfolio
Business Wire
23-04-2025
- Business
- Business Wire
Tenpoint Therapeutics Ltd. to Participate at Citi Biotech Private Access Day
LONDON & SEATTLE--(BUSINESS WIRE)-- Tenpoint Therapeutics, Ltd. ('Tenpoint'), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, will participate in one-on-one meetings at the virtual Citi Biotech Private Access Day on April 24. Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, will participate in one-on-one meetings at the virtual Citi Biotech Private Access Day on April 24. Share About Tenpoint Therapeutics Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. BRIMOCHOL PF has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) and has submitted its NDA to the US FDA. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, AlbionVC, British Business Bank (formerly British Patient Capital), Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and Wille AG. To learn more, visit and connect on LinkedIn.
Yahoo
31-03-2025
- Business
- Yahoo
Seaport Therapeutics to Participate in Upcoming Investor Conferences in April
BOSTON, March 31, 2025--(BUSINESS WIRE)--Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences: 24th Annual Needham Healthcare Conference The Seaport management team was invited to present on Monday, April 7th at 3:45pm EDT. The live and archived webcast will be available under the Events section of the Company's website at Management will also participate in one-on-one meetings at the conference. Citi Biotech Private Access Day The Seaport management team was invited to participate in one-on-one meetings at the virtual conference on April 24th. About Seaport Therapeutics Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph™ technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit View source version on Contacts Public Relationspublicrelations@ Investor Relationsir@
